---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Expected outcomes of therapy"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Expected outcomes of therapy. Topics: Cardiovascular benefit per 5 mm Hg reduction in systolic blood pressure, Cardiovascular benefit per 10 mm Hg reduction in systolic blood pressure, Blood pressure reduction as the basis of cardiovascular benefit: FDA guidance, Blood pressure reduction as the basis of cardiovascular benefit: ICER background, and 6 further topics. 11 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/expected-outcomes-of-therapy"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Expected outcomes of therapy

<a id="heading-2.2.2.7"></a>

## 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

### Summary

- Benefit per unit of blood pressure reduction: An individual participant-level meta-analysis of 48 trials found that each 5 mm Hg reduction in systolic blood pressure lowered the risk of major cardiovascular events by about 10%, with reductions of 13% for stroke, 13% for heart failure, 8% for ischemic heart disease, and 5% for cardiovascular death, irrespective of prior cardiovascular disease. A meta-analysis of 123 studies (613,815 participants) found that each 10 mm Hg reduction lowered major cardiovascular events (relative risk 0.80), coronary heart disease (0.83), stroke (0.73), heart failure (0.72), and all-cause mortality (0.87), with no significant effect on renal failure. FDA guidance attributes these benefits largely to the decrease in blood pressure itself across drug classes.
- Lorundrostat: In Launch-HTN, lorundrostat 50 mg lowered office systolic blood pressure by 9.1 mm Hg more than placebo at week 6. No trial of lorundrostat or baxdrostat reporting cardiovascular, kidney, or mortality outcomes was identified; the placebo-controlled Launch-HTN comparison lasted 12 weeks.
- Blood pressure as a surrogate: ICER states that blood pressure is a surrogate marker, that not all blood pressure drugs have the same effect on major adverse cardiovascular events and their effects on mortality are inconsistent, and that longer-term data are needed to determine the effect of aldosterone synthase inhibitors on patient-important outcomes. A review of FDA surrogate endpoints found 10 meta-analyses with inconsistent evidence on the strength of association between blood pressure reductions and cardiovascular outcomes and all-cause mortality. The Explore-OSA investigators state that a longer-term cardiovascular outcomes trial of lorundrostat should be considered.

Source: [Blood Pressure Lowering Treatment Trialists' Collaboration (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8102467/); [Ettehad et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26724178/); [FDA guidance, hypertension labeling for cardiovascular outcome claims (2011)](https://www.fda.gov/media/134777/download); [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/); [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf); [Wallach et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11036312/); [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-2.2.2.7-2"></a>

### Cardiovascular benefit per 5 mm Hg reduction in systolic blood pressure

> “In this large-scale analysis of randomised trials, a 5 mm Hg reduction of systolic blood pressure reduced the risk of major cardiovascular events by about 10%, irrespective of previous diagnoses of cardiovascular disease, and even at normal or high–normal blood pressure values.”
> “On average, a 5 mm Hg reduction of systolic blood pressure reduced the risk of a major cardiovascular event by about 10%; the corresponding proportional risk reductions for stroke, heart failure, ischaemic heart disease, and cardiovascular death were 13%, 13%, 8%, and 5%, respectively.”

Source: [Blood Pressure Lowering Treatment Trialists' Collaboration (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8102467/)

<a id="topic-2.2.2.7-3"></a>

### Cardiovascular benefit per 10 mm Hg reduction in systolic blood pressure

> “We identified 123 studies with 613,815 participants for the tabular meta-analysis.”
> “Every 10 mm Hg reduction in systolic blood pressure significantly reduced the risk of major cardiovascular disease events (relative risk [RR] 0·80, 95% CI 0·77-0·83), coronary heart disease (0·83, 0·78-0·88), stroke (0·73, 0·68-0·77), and heart failure (0·72, 0·67-0·78), which, in the populations studied, led to a significant 13% reduction in all-cause mortality (0·87, 0·84-0·91).”
> “However, the effect on renal failure was not significant (0·95, 0·84-1·07).”
> “There was no clear evidence that proportional risk reductions in major cardiovascular disease differed by baseline disease history, except for diabetes and chronic kidney disease, for which smaller, but significant, risk reductions were detected.”

Source: [Ettehad et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26724178/)

<a id="topic-2.2.2.7-4"></a>

### Blood pressure reduction as the basis of cardiovascular benefit: FDA guidance

> “The similar effects with multiple drug classes with disparate mechanisms of action indicate that it is the decrease in blood pressure, rather than any other property of the drugs, that is largely responsible for these benefits.”

Source: [FDA guidance, hypertension labeling for cardiovascular outcome claims (2011)](https://www.fda.gov/media/134777/download)

<a id="topic-2.2.2.7-5"></a>

### Blood pressure reduction as the basis of cardiovascular benefit: ICER background

> “a meta-analysis of nearly 50 randomized controlled trials demonstrated that a 5 mm Hg decrease in systolic blood pressure was associated with a roughly 10% decrease in major adverse cardiovascular events (MACE).”
> “However, blood pressure is a surrogate marker and not all blood pressure drugs have the same effect on MACE, and their effects on mortality are also inconsistent.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.2.7-6"></a>

### Blood pressure as a surrogate marker: strength of evidence

> “Of 5541 records screened, 10 meta-analyses offered inconsistent evidence on the strength of association between reductions in systolic or diastolic blood pressure and improvements in cardiovascular outcomes and all-cause mortality (eTable 10 and eFigure 26 in Supplement 1).”

Source: [Wallach et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11036312/)

<a id="topic-2.2.2.7-7"></a>

### Lorundrostat blood pressure effect in the phase 3 trial

> “For the pooled 50 mg of lorundrostat group (n = 808), the least-squares mean change in automated office systolic BP at week 6 was −16.9 mm Hg (95% CI, −19.0 to −14.9 mm Hg) vs −7.9 mm Hg (95% CI, −11.5 to −4.2 mm Hg) for the placebo group (least-squares mean difference, −9.1 mm Hg [95% CI, −13.3 to −4.9 mm Hg]; P < .001).”
> “First, the efficacy and safety of lorundrostat compared with placebo was evaluated for only 12 weeks.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-2.2.2.7-8"></a>

### Absence of outcome data for aldosterone synthase inhibitors

> “The pivotal trials for baxdrostat and lorundrostat measured short-term changes in systolic blood pressure, which is a surrogate endpoint.”
> “Although a reduction in blood pressure has been associated with an overall decrease in major adverse cardiovascular events (MACE) and progression of chronic kidney disease, not all drugs affect all components of MACE or decrease mortality.”
> “Additional, longer-term data for baxdrostat and lorundrostat are necessary to determine their impact on patient-important outcomes.”
> “Finally, we await the long-term extension study for lorundrostat, as there may be different effects, even for drugs within the same class.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

> “Given the high prevalence of aldosterone dysregulation and its association with cardiometabolic disease in OSA, a longer-term CV outcomes trial of lorundrostat should be considered.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-2.2.2.7-9"></a>

### Expected benefit of a new class: ICER

> “Thus, a new class of effective antihypertensive medications with a favorable side effect profile could help increase the number of patients with hypertension who reach their blood pressure goals and potentially see a decrease in cardiovascular or kidney events.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.2.7-10"></a>

### Expected benefit as stated by the manufacturer

> “In a meta-analysis of 147 randomized trials, a 10 mmHg reduction in systolic BP or a 5 mmHg reduction in diastolic BP has been shown to reduce the risk of stroke by 41% and coronary heart disease by 22%.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.2.2.7-11"></a>

### Blood pressure as a modifiable risk factor: guideline

> “High blood pressure is the most prevalent and modifiable risk factor for the development of cardiovascular diseases, including coronary artery disease, heart failure, atrial fibrillation, stroke, dementia, chronic kidney disease, and all-cause mortality.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
